الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
intralesional immunotherapy with MMR and BCG vaccines seems to be promising effective and safe treatment modalities for common warts, including single, multiple and recalcitrant variants. They are inexpensive and have the potential advantages of widespread and sustained effects against HPV. Based on the results of this study, MMR is more suitable for patients presenting with multiple warts associated with distant lesions, while BCG vaccine is more suitable for single or few lesions, particularly the resistant ones, owing to its induction of pronounced inflammatory response. The mode of action of both vaccines is still obscure, but is most probably mediated through stimulation of Th1 cytokine profile.
the widespread use of MMR and BCG vaccines in the treatment of different types of warts, at different age groups, on a much larger scale and in comparison with other traditional therapeutic modalities to accurately define their place in the challenging field of wart therapy.